VK Tech announced a partnership with Productos Medix in Mexico. The licensing agreement awards Medix a license for the manufacture, distribution, and marketing of Lomaira (phentermine hydrochloride USP) 8 mg tablets, CIV in Mexico.
Lomaira is an appetite suppressant available by prescription only and used for a short period of time for weight reduction in adults with an initial body mass index (BMI) of 30 or more or 27 or more with a weight-related condition such as controlled high blood pressure, diabetes, or high cholesterol. BMI measures the amount of fat in the body based on height and weight and is measured in kg/m2. Lomaira should be used together with increased physical activity and a reduced-calorie diet.
Medix plans to work with its current physician network and portfolio of more than 10 products for weight loss. According to Mario Lazcano, Legal VP of Medix, the current market for prescription medicine for obesity in Mexico is about US$ 250 million. The licensing agreement includes milestone payments and royalties to be paid to KVK.
"We're thrilled to partner with Medix, a trusted leader in the obesity space in Mexico, as it allows KVK to expand into international markets and open a new channel of distribution in the weight-loss industry," said Kiran Vepuri, Director of Business Development at KVK. "Mexico has the second largest population with obesity in the world and Lomaira offers patients another weight-loss treatment option to meet their lifestyle needs."
Lomaira is a low dose medicine for weight loss in the U.S. (phentermine). Now the flexible dosing options of Lomaira provide a unique opportunity for patients to take a modest dose when they need it, especially before the evening meal when appetite is the greatest. Unlike the higher strengths of phentermine HCl that are dosed once a day before or shortly after breakfast, Lomaira is FDA-approved to be used up to 3x daily before each meal.